Shots:

• Collegium commences a tender offer to acquire all outstanding shares of BDSI at $5.60 per share in an all-cash transaction making a total deal value of $604M. It represents 54% premium to BDSI common stock’s closing price of $3.64 on Feb 11, 2022
• After the completion of the tender offer, Collegium to acquire all remaining shares at the same price of $5.60 per share via second step merger. The transaction is expected to be completed in Q1’22
• The addition of BDSI's Belbuca which is a schedule III opioid product complements Collegium's portfolio of pain products. BDSI other product includes Symproic and Elyxyb

 Ref: Globe Newswire | Image: Twitter